Aclaris Therapeutics (ACRS) AI Stock Analysis

• Market Cap: $383.54M
• Dividend Yield: N/A
• Average Volume (3M): 1.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -41.87%
• EPS Growth: -165.76%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.12
• Shares Outstanding: 108,345,240
• 10 Day Avg. Volume: 1,094,755
• 30 Day Avg. Volume: 1,106,653
• PEG Ratio: -0.04
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 10.24
• P/FCF Ratio: -9.49
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 22.90
• Enterprise Value/Gross Profit: 101.64
• Enterprise Value/Ebitda: -5.74
• 1Y Price Target: $11.33
• Price Target Upside: 220.06% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $3.50 ▼(-1.13% Downside)

The score is held back primarily by weak financial performance (deep losses, declining TTM revenue, and ongoing cash burn), despite a low-leverage balance sheet. Technicals add support due to strong upward price trends, but overbought signals increase near-term risk. Positive pipeline-related corporate events help, while valuation remains unfavorable given negative earnings and no dividend support.

Positive Factors

Low leverage balance sheet

Very low debt-to-equity reduces refinancing and interest risk, giving management flexibility to fund clinical programs and pursue partnerships. A stronger balance sheet supports multi-year R&D investment and strategic optionality, lowering solvency risk during development timelines.

Strong Phase 1a ATI-052 data

Favorable first-in-human safety, extended half-life and concentration-dependent pharmacodynamics suggest ATI-052 could enable infrequent dosing and meaningful pathway coverage. If reproduced in POC and later trials, this provides durable clinical differentiation across chronic immuno-inflammatory indications.

Broadened inflammation pipeline

A wider pipeline across oral and multispecific antibody programs reduces single-program dependency and creates multiple 2026 value inflection points. Emphasis on partnerships and capital discipline structurally improves commercialization optionality and risk diversification over the medium term.

Negative Factors

Deep unprofitability and negative margins

Sustained large operating losses erode shareholder equity and heighten the need for external funding. Very negative margins indicate current operations cannot self-finance growth, increasing dilution risk and pressuring long-term viability unless offset by successful partnering or commercialization.

Negative operating and free cash flow

Ongoing negative OCF and FCF mean Aclaris relies on external capital to progress trials. This elevates execution risk if markets or funding windows tighten, may force dilutive financings or strategic trade-offs, and constrains ability to invest opportunistically across its multi-year R&D roadmap.

Declining recent revenue trend

A recent TTM revenue decline amid heavy R&D and SG&A weakens operating leverage and exacerbates cash burn. Lower top-line traction reduces internal funding capacity for development, increases dependence on partners or capital markets, and raises the bar for achieving sustainable profitability.

Aclaris Therapeutics Business Overview & Revenue Model

Company Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

How the Company Makes Money

Aclaris Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding through various streams, including upfront payments and milestone payments from partnerships with larger pharmaceutical companies, as well as royalties on product sales. Additionally, Aclaris may also generate revenue from licensing agreements that allow other companies to develop or market its drug candidates. The company actively seeks collaborations to enhance its research capabilities and expand its market reach, which contributes to its overall earnings.

Aclaris Therapeutics Financial Statement Overview

Summary

Financials are weak overall: the company remains deeply unprofitable with TTM revenue down (-6.2%), extremely negative margins, and negative operating/free cash flow. The main offset is a relatively strong balance sheet with very low leverage (debt-to-equity ~0.02), but continued losses and cash burn elevate funding and execution risk.

Income Statement

ACRS remains deeply unprofitable, with very large losses versus a small revenue base. TTM (Trailing-Twelve-Months) revenue declined (-6.2%) and profitability is materially negative (net margin around -8.0x; EBIT and EBITDA margins also strongly negative), indicating heavy ongoing operating spend. A positive is that revenue has scaled up versus 2020–2021 levels, but the more recent trajectory shows weakening top-line and no clear progress toward break-even.

Balance Sheet

The balance sheet is a relative strength: leverage is very low (TTM debt-to-equity ~0.02) and equity remains sizable. However, sustained net losses are eroding shareholder value (TTM return on equity ~-96%), and equity has trended down from prior years, which increases long-run financing risk if losses continue.

Cash Flow

Cash generation is weak, with negative operating cash flow and negative free cash flow in TTM (Trailing-Twelve-Months). While free cash flow improved versus the prior period (strong positive growth rate), the business is still consuming significant cash, and operating cash flow remains negative—suggesting continued reliance on the balance sheet and/or external funding until profitability improves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.74M	18.72M	31.25M	29.75M	6.76M	6.48M
Gross Profit	3.55M	15.93M	13.17M	17.79M	2.05M	1.35M
EBITDA	-62.78M	-51.72M	-115.45M	-84.36M	-64.46M	-47.20M
Net Income	-141.68M	-132.06M	-88.48M	-86.91M	-90.86M	-51.02M
Balance Sheet
Total Assets	175.53M	220.33M	197.41M	254.60M	251.21M	70.78M
Cash, Cash Equivalents and Short-Term Investments	95.91M	113.59M	119.11M	217.57M	191.41M	54.13M
Total Debt	2.24M	0.00	426.00K	684.00K	693.00K	11.26M
Total Liabilities	55.43M	64.77M	40.23M	56.98M	53.87M	33.13M
Stockholders Equity	120.10M	155.55M	157.18M	197.62M	197.34M	37.65M
Cash Flow
Free Cash Flow	-78.82M	-20.20M	-79.63M	-68.17M	-52.44M	-39.09M
Operating Cash Flow	-42.92M	-20.07M	-78.33M	-67.57M	-52.13M	-38.63M
Investing Cash Flow	-50.73M	-69.77M	46.22M	12.63M	-167.63M	6.39M
Financing Cash Flow	71.25M	74.54M	26.71M	72.87M	225.05M	18.37M

Aclaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Positive. The current price of 3.54 is above the 20-day moving average (MA) of 3.40, above the 50-day MA of 3.14, and above the 200-day MA of 2.08, indicating a bullish trend. The MACD of 0.17 indicates Positive momentum. The RSI at 53.54 is Neutral, neither overbought nor oversold. The STOCH value of 10.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRS.

Aclaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACRS	54 Neutral	$383.54M	-2.56	-113.23%	―	-41.87%	-165.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SERA	48 Neutral	$101.50M	-3.42	-47.69%	―	1.06%	22.41%
MDXH	44 Neutral	$175.22M	-5.56	-720.01%	―	21.68%	58.30%
STIM	44 Neutral	$106.15M	-1.88	-239.53%	―	78.62%	32.39%
XGN	44 Neutral	$79.55M	-3.79	-122.81%	―	14.08%	1.34%
NOTV	43 Neutral	$15.31M	-0.20	-44.77%	―	4.54%	47.11%

Aclaris Therapeutics Corporate Events

Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy

On January 12, 2026, Aclaris Therapeutics updated its corporate overview presentation to highlight a broadened inflammation and immunology pipeline and a strategy centered on innovative oral and bispecific or multispecific antibody therapies for Th1-, Th2- and Th17-mediated diseases. The presentation underscored four anticipated clinical programs and multiple potential value inflection points in 2026, including progress on bosakitug (ATI-045), ATI-052, ATI-2138, next-generation ITK-selective inhibitors, and bispecific antibodies across dermatology, respiratory and gastrointestinal indications, while emphasizing prudent capital management and the need for strategic partnerships, moves that could materially influence its competitive position and long-term growth prospects in large, underserved markets.

The most recent analyst rating on (ACRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.

Aclaris advances ATI-052 after positive Phase 1a results

On January 6, 2026, Aclaris Therapeutics reported positive interim data from a first-in-human Phase 1a single and multiple ascending dose trial of its bispecific antibody ATI-052 in healthy adults, showing the drug was well tolerated up to 720 mg with mostly mild, self-resolving injection site reactions and no serious adverse events or discontinuations. The study demonstrated a potentially best-in-class pharmacokinetic profile with an effective half-life of at least 26 days and dose-proportional exposure, alongside robust pharmacodynamic effects including strong target engagement and sustained inhibition of key inflammatory markers at low doses, supporting the possibility of dosing as infrequently as once every three months. On the back of these results, the company moved to rapidly advance ATI-052’s development, planning imminent initiation of Phase 1b proof-of-concept trials in atopic dermatitis and asthma in the first quarter of 2026, with top-line data expected in the second half of 2026 and a Phase 2b trial in atopic dermatitis slated to start in the same period, potentially strengthening Aclaris’s position in the competitive immunology and allergy market if later-stage trials confirm these early findings.

The most recent analyst rating on (ACRS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.